ANN ARBOR, Mich., Jan. 24, 2023 — Fifth Eye™, a leading provider of intuitive real-time clinical analytics, today announced the addition of Tricia Strong as Senior Director of Marketing.
With over fifteen years of progressive management experience in the medical device, finance, and health care delivery industries, Tricia is versed in brand and portfolio strategy, market development, new product launches, and commercial strategy. Tricia previously directed full-spectrum marketing operations for Bolder Surgical, bringing six new surgical devices from concept to globalization in 2.5 years, leading to the company being recognized as one of Fast Company’s Most Innovative Medical Device Companies. The company was acquired by Hologic, Inc. for $160 million in 2021.
Prior to joining Bolder Surgical, Tricia led Global Upstream Marketing for the peripheral vascular business unit at Philips Healthcare where she partnered across the business and geographies to ensure alignment on global growth strategies and the portfolio map. Tricia previously led marketing teams with R&D and product launch responsibilities for Spectranetics before the company was acquired for $2.2B in 2017.
Tricia studied Advanced Program Management at Stanford University and earned an MBA from the Carlson School of Business, University of Minnesota.
“I am delighted to join Fifth Eye at this exciting point in the development of the company,” Strong said. “Our technology is focused on solving the very real issues that hospitals face today in providing better, more affordable patient care. The opportunity to contribute to the chapter of growth that we are entering now is truly exciting.”
According to Fifth Eye President and CEO Andrew Malcolmson, “We are so happy to welcome Tricia to the team. She brings an impressive track record in bringing medical technology from concept to adoption. She joins us at a pivotal point in our company’s progress, and I am confident she will play a key role in our future success.”
About Fifth Eye Inc.
Fifth Eye Inc. is an Ann Arbor, Michigan-based company that develops intuitive, real-time clinical analytics based on physiologic waveforms to improve outcomes and reduce costs. The AHI System™ is the first and only FDA-cleared clinical decision support software that continuously predicts the risk of hemodynamic instability earlier than vital signs. AI-powered AHI extracts information embedded in a Lead II ECG signal alone – no manual or other inputs required. Fifth Eye’s machine-learning technology is licensed from the University of Michigan. For more information, please visit www.fiftheye.com.